Wedbush Reiterates Outperform on Cogent Biosciences, Maintains $55 Price Target

Benzinga Newsdesk www.benzinga.com Negative 56.6%

Neg 56.6% Neu 0% Pos 0%

Wedbush analyst David Nierengarten reiterates Cogent Biosciences (NASDAQ:COGT) with a Outperform and maintains $55 price target.